DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, H.
Right arrow Articles by Riggs, K. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, H.
Right arrow Articles by Riggs, K. W.

Vol. 29, Issue 5, 664-675, May 2001

Dose-Dependent Pharmacokinetics and Metabolism of Valproic Acid in Newborn Lambs and Adult Sheep

Harvey Wong, Dan W. Rurak, Sanjeev Kumar, Eddie Kwan, Frank S. Abbott, and K. Wayne Riggs

Faculty of Pharmaceutical Sciences (H.W., S.K., E.K., F.S.A., K.W.R.) and British Columbia Research Institute for Children's and Women's Health, Department of Obstetrics and Gynecology, Faculty of Medicine (D.W.R.), The University of British Columbia, Vancouver, British Columbia, Canada

Dose-dependent pharmacokinetics and metabolism of valproic acid (VPA) were studied in newborn and adult sheep to assess age-related differences in plasma protein binding and metabolic elimination. Newborn lambs received either a 10- (n = 8), 50- (n = 5), 100- (n = 4), or 250-mg/kg (n = 4) VPA i.v. bolus. Individual adult sheep (n = 5) received all four doses in a random order with an appropriate washout period between experiments. Unbound or metabolic clearance of VPA was significantly higher in adult sheep at the two lower doses when compared with lambs, and similar to the lambs at the two higher doses. Plasma protein binding was nonlinear at all doses. Estimates of binding capacity (Bmax1) at the saturable site were higher in adults (91.8 µg/ml) when compared with lambs (44.9 µg/ml), whereas the opposite trend was observed for binding affinity [Kd1 = 9.6 µg/ml (adult) versus 3.2 µg/ml (lambs)]. Characterization of developmental differences in overall VPA metabolic elimination involved fitting of unbound VPA plasma concentration data to a two-compartment model with Michaelis-Menten elimination. This resulted in similar in vivo estimates of apparent Vmax [445.0 µg/min/kg (adult) versus 429.9 µg/min/kg (lambs)]. However, apparent Km estimates appeared to be higher in lambs [30.0 µg/ml (adult) versus 69.6 µg/ml (lambs)]. Similar findings were obtained from in vivo estimates of Vmax and Km for VPA glucuronidation obtained from VPA-glucuronide metabolite urinary excretion data. Thus, it appears that age-related differences in metabolic clearance may be related to differences in the apparent in vivo Km as opposed to Vmax of VPA glucuronidation.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
H. Wong, V. Tong, K. W. Riggs, D. W. Rurak, F. S. Abbott, and S. Kumar
Kinetics of Valproic Acid Glucuronidation: Evidence for in Vivo Autoactivation
Drug Metab. Dispos., August 1, 2007; 35(8): 1380 - 1386.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Achachi, A. Florins, N. Gillet, C. Debacq, P. Urbain, G. M. Foutsop, F. Vandermeers, A. Jasik, M. Reichert, P. Kerkhofs, et al.
Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo
PNAS, July 19, 2005; 102(29): 10309 - 10314.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.